Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma
Authors
Keywords
PD-1, Sorafenib, Phosphorylation, Therapeutic antibody, Oncogene
Journal
TUMOR BIOLOGY
Volume 36, Issue 3, Pages 1561-1566
Publisher
Springer Nature
Online
2014-11-05
DOI
10.1007/s13277-014-2722-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies
- (2014) Wenyan Fu et al. mAbs
- Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View
- (2013) Shi Hu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Sox Transcription Factors Require Selective Interactions with Oct4 and Specific Transactivation Functions to Mediate Reprogramming
- (2013) Irene Aksoy et al. STEM CELLS
- Estrogen regulation of Dkk1 and Wnt/β-Catenin signaling in neurodegenerative disease
- (2012) Erin L. Scott et al. BRAIN RESEARCH
- Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients
- (2012) Claudio Coco et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Mapping of DNA Sex-Specific Markers and Genes Related to Sex Differentiation in Turbot (Scophthalmus maximus)
- (2012) Ana Viñas et al. MARINE BIOTECHNOLOGY
- Deciphering the Sox-Oct partner code by quantitative cooperativity measurements
- (2012) Calista K. L. Ng et al. NUCLEIC ACIDS RESEARCH
- Molecular Targeted Therapies in Hepatocellular Carcinoma
- (2012) Shinji Tanaka et al. SEMINARS IN ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Sox2 Activates Cell Proliferation and Differentiation in the Respiratory Epithelium
- (2010) David H. Tompkins et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- SOX2 Is an Oncogene Activated by Recurrent 3q26.3 Amplifications in Human Lung Squamous Cell Carcinomas
- (2010) Thomas Hussenet et al. PLoS One
- Sex Determining Region Y-Box 2 (SOX2) Is a Potential Cell-Lineage Gene Highly Expressed in the Pathogenesis of Squamous Cell Carcinomas of the Lung
- (2010) Ping Yuan et al. PLoS One
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
- (2009) Adam J Bass et al. NATURE GENETICS
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sox2 Is Required for Maintenance and Differentiation of Bronchiolar Clara, Ciliated, and Goblet Cells
- (2009) David H. Tompkins et al. PLoS One
- Epigenetic Inactivation of the Canonical Wnt Antagonist SRY-Box Containing Gene 17 in Colorectal Cancer
- (2008) W. Zhang et al. CANCER RESEARCH
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search